50,823.7
(-623.5)
(-1.21%)
17 Jul , 2026 | 03:39 PM
Open
51,469.3
Prev. Close
51,447.2
Market Cap.
₹0
Div Yield
0.32
PE
46.54
PB
46.54
50,493.6
51,489.1
Performance
One Week (%)
1.61
One Month (%)
8.16
One Year (%)
13.62
YTD (%)
22.41
Company Name | CMP | High | Low | Volume |
|---|---|---|---|---|
Abbott India Ltd | 28,055 | 28,170 | 27,445 | 11,096 |
Glaxosmithkline Pharmaceuticals Ltd | 2,454.8 | 2,510.6 | 2,430 | 55,499 |
Pfizer Ltd | 4,566.9 | 4,609 | 4,502.6 | 32,717 |
Lupin Ltd | 2,443.2 | 2,489.6 | 2,428 | 6,78,348 |
Ipca Laboratories Ltd | 1,900.6 | 1,944.9 | 1,846.8 | 1,57,253 |
Neuland Laboratories Ltd | 18,434 | 18,951 | 18,055 | 40,522 |
Aurobindo Pharma Ltd | 1,533.4 | 1,550 | 1,520.4 | 5,18,019 |
Natco Pharma Ltd | 943.15 | 968.5 | 940.1 | 3,37,731 |
Wockhardt Ltd | 1,900.7 | 1,908 | 1,825 | 6,83,030 |
Granules India Ltd | 880.8 | 902.75 | 870.15 | 16,99,239 |
Ajanta Pharma Ltd | 3,419.4 | 3,454 | 3,341.1 | 93,411 |
Poly Medicure Ltd | 1,680.5 | 1,739 | 1,667.1 | 84,067 |
Gland Pharma Ltd | 2,449 | 2,539 | 2,435 | 3,26,955 |
Biocon Ltd | 437.2 | 444.45 | 432.8 | 88,10,327 |
Alkem Laboratories Ltd | 5,563 | 5,709 | 5,539 | 70,579 |
Glenmark Pharmaceuticals Ltd | 2,235.5 | 2,287.9 | 2,229 | 3,55,894 |
Fortis Healthcare Ltd | 952.45 | 964 | 944 | 6,04,686 |
Syngene International Ltd | 417.45 | 420.9 | 410.1 | 4,87,906 |
Global Health Ltd | 1,316.9 | 1,337.9 | 1,312.6 | 58,337 |
Krishna Institute of Medical Sciences Ltd | 802.95 | 808.05 | 792.05 | 2,43,386 |
Mankind Pharma Ltd | 2,484.2 | 2,558.4 | 2,469.5 | 3,61,918 |
Dr Lal Pathlabs Ltd | 1,687.4 | 1,733 | 1,666.2 | 2,12,534 |
Narayana Hrudayalaya Ltd | 2,029.5 | 2,043 | 2,004 | 1,67,202 |
Laurus Labs Ltd | 1,527.5 | 1,561 | 1,520.4 | 10,10,976 |
Sai Life Sciences Ltd | 1,272 | 1,294 | 1,265.2 | 2,01,168 |
Aster DM Healthcare Ltd | 819.9 | 825.6 | 812.05 | 5,34,598 |
Acutaas Chemicals Ltd | 3,619.4 | 3,634 | 3,545 | 1,87,906 |
Cohance Lifesciences Ltd | 442 | 473.7 | 431 | 37,95,556 |
Piramal Pharma Ltd | 179.42 | 181.6 | 172.1 | 66,89,114 |
OneSource Specialty Pharma Ltd | 1,653.2 | 1,665 | 1,625.5 | 1,90,052 |
The National Stock Exchange (NSE) will launch derivatives on the Nifty India FPI 150 Index from August 12 after receiving SEBI approval. The new futures and options contracts are expected to strengthen risk management, improve market liquidity, and provide foreign investors with a diversified benchmark for Indian equities.
17 Jul 2026|10:10 AM
Indian benchmark indices ended largely unchanged on July 16, 2026, with IT and Auto stocks supporting the market while Realty and Financial Services lagged. Rising Brent crude prices, fresh US-Iran tensions, weak global cues, and profit booking ahead of the Q1 earnings season kept investor sentiment cautious despite selective sectoral gains.
16 Jul 2026|05:38 PM
Sensex and Nifty ended nearly flat after recovering from sharp early losses. A strong rally in TCS, HCL Tech, and the IT sector offset weakness in FMCG, metals, and defence stocks amid geopolitical concerns and higher crude oil prices.
13 Jul 2026|05:30 PM
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
